Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R T D'Aquila

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
The Journal of Infectious Diseases|March 9, 1999
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study TeamR L Murphy, R M Gulick, V DeGruttola, et al.
The Journal of Infectious Diseases|March 14, 1998
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 TeamJ L Lathey, M D Hughes, S A Fiscus, et al.
JAMA|May 18, 2000
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA PanelM S Hirsch, F Brun-Vézinet, R T D'Aquila, et al.
The Journal of Infectious Diseases|December 26, 2001
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapyJ L Lathey, C Tierney, S Y Chang, et al.
JAMA|June 27, 1998
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA PanelM S Hirsch, B Conway, R T D'Aquila, et al.
Journal of Virology|October 24, 2000
Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sitesA J Brown, H M Precious, J M Whitcomb, et al.
The Journal of Infectious Diseases|October 1, 1996
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working GroupsR W Coombs, S L Welles, C Hooper, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2000
Antiretroviral resistance during successful therapy of HIV type 1 infectionJ Martinez-Picado, M P DePasquale, N Kartsonis, et al.
JAMA|September 29, 1999
Reduced antiretroviral drug susceptibility among patients with primary HIV infectionS J Little, E S Daar, R T D'Aquila, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
The Journal of Infectious Diseases|March 9, 1999
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study TeamR L Murphy, R M Gulick, V DeGruttola, et al.
The Journal of Infectious Diseases|March 14, 1998
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 TeamJ L Lathey, M D Hughes, S A Fiscus, et al.
JAMA|May 18, 2000
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA PanelM S Hirsch, F Brun-Vézinet, R T D'Aquila, et al.
The Journal of Infectious Diseases|December 26, 2001
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapyJ L Lathey, C Tierney, S Y Chang, et al.
JAMA|June 27, 1998
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA PanelM S Hirsch, B Conway, R T D'Aquila, et al.
Journal of Virology|October 24, 2000
Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sitesA J Brown, H M Precious, J M Whitcomb, et al.
The Journal of Infectious Diseases|October 1, 1996
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working GroupsR W Coombs, S L Welles, C Hooper, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2000
Antiretroviral resistance during successful therapy of HIV type 1 infectionJ Martinez-Picado, M P DePasquale, N Kartsonis, et al.
JAMA|September 29, 1999
Reduced antiretroviral drug susceptibility among patients with primary HIV infectionS J Little, E S Daar, R T D'Aquila, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
Pageof 7